Aerovate Therapeutics Inc. is a clinical stage biopharmaceutical company. It focused on developing drugs for cardiopulmonary disease. The company's product pipeline consist AV-101. Aerovate Therapeutics Inc. is based in BOSTON.
Info & Links
CEO
Timothy P. Noyes
Headquarters
930 Winter Street,Suite M-500 Waltham, MA 02451, UNITED STATES
Aerovate Therapeutics, Inc. Common Stock Statistics
Valuation Measures
Market Capitalization2
70.17M
Enterprise Value
39.05M
Enterprise Value/EBITDA(ttm)
-0.42
Price to Earnings Ratio(ttm)
--
Price to Sales(ttm)
--
Price to Book(mrq)
0.86
Price to Cash(ytd)
--
Profitability
Gross Margin(ttm)
0.00%
Operating Margin(ttm)
--
Profit Margin(ttm)
0.00%
Return on Equity(ttm)
-90.19%
Return on Invested Capital(ttm)
-90.57%
Return on Assets(ttm)
-77.47%
Income Statement
Revenue(ttm)
0.00
Revenue Per Share(ttm)
0.00
Gross Profit(ttm)
0.00
EBITDA(ttm)3
-92.81M
Net Income Available to Common(ttm)
-84.61M
Diluted EPS(ttm)
-2.99
Share Statistics
Beta (5Y Monthly)
0.99
52-Week Change
-87.58%
S&P 500 52-Week Change
18.02%
S&P 500 Member
Yes
Stock Optionable
Yes
Total Shares Outstanding1
28.87M
Dividend Yield
0.00%
Float4
21.68M
% Held by Insiders
24.90%
% Held by Institutions
--
Balance Sheet
Total Cash(mrq)
88.73M
Total Cash Per Share(mrq)
3.07
Total Debt(mrq)
0.00
Total Debt/Equity(mrq)
0.00%
Current Ratio(mrq)
8.78%
Quick Ratio(mrq)
8.78%
Book Value Per Share(mrq)
2.79
Cash Flow
Operating Cash Flow Per Share(ytd)
-2.08
Free Cash Flow(ytd)
-60.15M
Table Key
mrq = Most Recent Quarter
ttm = Trailing Twelve Months
ytd = Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.
1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.